203 related articles for article (PubMed ID: 9528836)
1. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
Remacle AG; Noël A; Duggan C; McDermott E; O'Higgins N; Foidart JM; Duffy MJ
Br J Cancer; 1998 Mar; 77(6):926-31. PubMed ID: 9528836
[TBL] [Abstract][Full Text] [Related]
2. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer.
McCarthy K; Maguire T; McGreal G; McDermott E; O'Higgins N; Duffy MJ
Int J Cancer; 1999 Feb; 84(1):44-8. PubMed ID: 9988231
[TBL] [Abstract][Full Text] [Related]
3. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma.
Sier CF; Kubben FJ; Ganesh S; Heerding MM; Griffioen G; Hanemaaijer R; van Krieken JH; Lamers CB; Verspaget HW
Br J Cancer; 1996 Aug; 74(3):413-7. PubMed ID: 8695357
[TBL] [Abstract][Full Text] [Related]
4. Detection of matrix metalloproteinase activity in human pancreatic cancer.
Koshiba T; Hosotani R; Wada M; Fujimoto K; Lee JU; Doi R; Arii S; Imamura M
Surg Today; 1997; 27(4):302-4. PubMed ID: 9086544
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases.
Quesada AR; Barbacid MM; Mira E; Fernández-Resa P; Márquez G; Aracil M
Clin Exp Metastasis; 1997 Jan; 15(1):26-32. PubMed ID: 9009103
[TBL] [Abstract][Full Text] [Related]
6. Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays.
Zucker S; Mancuso P; DiMassimo B; Lysik RM; Conner C; Wu CL
Clin Exp Metastasis; 1994 Jan; 12(1):13-23. PubMed ID: 8287615
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours.
Rooprai HK; Van Meter T; Rucklidge GJ; Hudson L; Everall IP; Pilkington GJ
Int J Oncol; 1998 Dec; 13(6):1153-7. PubMed ID: 9824624
[TBL] [Abstract][Full Text] [Related]
8. Localization of matrix metalloproteinases and tissue inhibitor of metalloproteinases-2 in normal human and rabbit stomachs.
Tatsuguchi A; Fukuda Y; Ishizaki M; Yamanaka N
Digestion; 1999; 60(3):246-54. PubMed ID: 10343138
[TBL] [Abstract][Full Text] [Related]
9. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas.
Iwata H; Kobayashi S; Iwase H; Masaoka A; Fujimoto N; Okada Y
Jpn J Cancer Res; 1996 Jun; 87(6):602-11. PubMed ID: 8766524
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.
Nakano A; Tani E; Miyazaki K; Yamamoto Y; Furuyama J
J Neurosurg; 1995 Aug; 83(2):298-307. PubMed ID: 7616276
[TBL] [Abstract][Full Text] [Related]
11. Local activity of matrix metalloproteinases in a case of botryoid sarcoma.
Rechberger T; Postawski K; Skorupski P; Kotarski J; Jakowicki JA
Eur J Obstet Gynecol Reprod Biol; 1996 Aug; 67(2):169-72. PubMed ID: 8841807
[TBL] [Abstract][Full Text] [Related]
12. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.
Ueno H; Nakamura H; Inoue M; Imai K; Noguchi M; Sato H; Seiki M; Okada Y
Cancer Res; 1997 May; 57(10):2055-60. PubMed ID: 9158005
[TBL] [Abstract][Full Text] [Related]
13. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinases in colorectal cancer.
Duncan ME; Murray GI; O'Neil P; Melvin WT; Fothergill JE
Biochem Soc Trans; 1996 May; 24(2):329S. PubMed ID: 8736987
[No Abstract] [Full Text] [Related]
15. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
16. Distribution of matrix metalloproteinases and their inhibitor, TIMP-1, in developing human osteophytic bone.
Bord S; Horner A; Hembry RM; Reynolds JJ; Compston JE
J Anat; 1997 Jul; 191 ( Pt 1)(Pt 1):39-48. PubMed ID: 9279657
[TBL] [Abstract][Full Text] [Related]
17. Metalloproteinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in endometrial flushings from pre- and post-menopausal women and from women with endometrial adenocarcinoma.
Laird SM; Dalton CF; Okon MA; Bunning RA; Marshall R; Li TC
J Reprod Fertil; 1999 Mar; 115(2):225-32. PubMed ID: 10434927
[TBL] [Abstract][Full Text] [Related]
18. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.
Davies B; Waxman J; Wasan H; Abel P; Williams G; Krausz T; Neal D; Thomas D; Hanby A; Balkwill F
Cancer Res; 1993 Nov; 53(22):5365-9. PubMed ID: 8221672
[TBL] [Abstract][Full Text] [Related]
19. 72-kDa and 92-kDa gelatinases in saliva of patients with human immunodeficiency virus infection.
Mellanen L; Salo T; Ingman T; Konttinen YT; Lähdevirta J; Sorsa T
Acta Odontol Scand; 1998 Jun; 56(3):135-42. PubMed ID: 9688221
[TBL] [Abstract][Full Text] [Related]
20. A study of metalloproteinases in fifty joint fluid specimens.
Gaudin P; Razakaboay M; Surla A; Berthier S; Fauconnier J; Morel F; Phelip X
Rev Rhum Engl Ed; 1997 Jun; 64(6):375-81. PubMed ID: 9513609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
